胰腺导管腺癌中的表观遗传学：对生物学的影响及其在诊断和治疗中的应用
Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment.
作者信息
Elrakaybi Asmaa, Ruess Dietrich A, Lübbert Michael, Quante Michael, Becker Heiko
机构信息
Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Department of Clinical Pharmacy, Ain Shams University, Cairo 11566, Egypt.
出版信息
Cancers (Basel). 2022 Nov 30;14(23):5926. doi: 10.3390/cancers14235926.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with high potential of metastases and therapeutic resistance. Although genetic mutations drive PDAC initiation, they alone do not explain its aggressive nature. Epigenetic mechanisms, including aberrant DNA methylation and histone modifications, significantly contribute to inter- and intratumoral heterogeneity, disease progression and metastasis. Thus, increased understanding of the epigenetic landscape in PDAC could offer new potential biomarkers and tailored therapeutic approaches. In this review, we shed light on the role of epigenetic modifications in PDAC biology and on the potential clinical applications of epigenetic biomarkers in liquid biopsy. In addition, we provide an overview of clinical trials assessing epigenetically targeted treatments alone or in combination with other anticancer therapies to improve outcomes of patients with PDAC.
胰腺导管腺癌（PDAC）是最具侵袭性的恶性肿瘤之一，具有高转移潜力和治疗抗性。尽管基因突变驱动了PDAC的起始，但仅靠它们并不能解释其侵袭性本质。表观遗传机制，包括异常的DNA甲基化和组蛋白修饰，显著促成了肿瘤间和肿瘤内的异质性、疾病进展和转移。因此，加深对PDAC表观遗传格局的理解可能会提供新的潜在生物标志物和量身定制的治疗方法。在本综述中，我们阐明了表观遗传修饰在PDAC生物学中的作用以及表观遗传生物标志物在液体活检中的潜在临床应用。此外，我们概述了评估单独或与其他抗癌疗法联合使用表观遗传靶向治疗以改善PDAC患者预后的临床试验。
Zotero 插件